Clear Cell Tumour

A benign or malignant neoplasm composed of clear cells that may be of any embryologic (endo-, ecto-, meso-) or neuroectodermal origin; the cytoplasmic clearing may be real—lipid, mucopolysaccharide and mucosubstance—or artifactual, due to post-fixation shrinkage of cytoplasmic content away from an intact and more rigid cell membrane
Examples, clear cell tumours Balloon cell melanoma, signet ring cell carcinomas, renal cell, adrenal, ovary, parathyroid and thyroid carcinomas, clear cell tumours of tendons & aponeuroses, germ cell tumours—e.g., seminomas, dysgerminoma—histiocytosis X, lymphoma—B- and T- clear cell lymphomas—myeloma, clear cell type, myxoid lesions—benign and malignant—paraganglioma, and xanthoma. See Clear cell carcinoma

Mentioned in ?

sugar tumor

References in periodicals archive ?

Histologically, both ovaries consisted of a clear cell tumour arranged in a solid, alveolar, microcystic and macrocystic pattern and showed a prominent vascular network (Fig.

Ovarian metastasis of clear cell renal cell carcinoma: A case report

8.: On the left, low power magnification of thrombus showing cast-like shape containing a clear cell tumour. On the right, high power view shows large cells with cleared cytoplasm consistent with renal cell carcinoma.

Unanticipated intra-operative finding of pulmonary artery tumour thromboembolism during radical nephrectomy and caval thrombectomy: Case report and management

The pathological differential diagnosis of MEC of the lacrimal gland may include inverted duct papillomas, cheilitis glandularis, necrotizing sialometaplasia, cystadenoma, cystadenocarcinoma, sebaceous carcinoma and other clear cell tumours, adenosquamous carcinoma, metastatic squamous cell carcinoma, and rarely pleomorphic adenoma.

Low-Grade Mucoepidermoid Carcinoma of the Lacrimal Gland in a Teenaged Patient

Our sub-analysis of the 544 clear cell tumours showed results similar to those of the larger cohort, with a tendency toward increased recurrence in patients who used metformin (HR, 1.7; 95% CI, 0.89-3.05[p = 0.09]), and no difference in CSS (HR, 0.9; 95% CI, 0.27-3.05 [p = 0.5]) (Fig.

The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma